Bispecific antibody · Cytotoxic, directed at B7-H3 (CD276) and PTK7 · developed by IDEAYA Biosciences
IDE034 is an antibody-drug conjugate built from a bispecific antibody that binds B7-H3 and PTK7, two antigens co-expressed on certain tumor cells, linked to a topoisomerase I inhibitor payload. The payload is released after internalization and inhibits DNA topoisomerase I, leading to cell cycle arrest and apoptosis. It is studied in multiple solid tumors, including esophageal, ovarian, head and neck, colorectal, prostate, lung, endometrial and triple negative breast cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07503808 | Phase 1 | Esophageal Squamous Cell Carcinoma | Recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-resistant Prostate CancerColorectal CancerEndometrium CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerNon Small Cell Lung CancerTriple Negative Breast Cancer
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →